ArticleSurgical neurology international2025
Vascular endothelial cadherin dysfunction: A predictor of hypertensive nonlobar intracerebral hemorrhage.
Article in Surgical neurology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structure and function of neurovascular unit in arterial hypertension.Frontiers in molecular neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endothelial dysfunction plays a key role in intracerebral hemorrhage (ICH), with vascular endothelial cadherin (VE-cadherin) being essential for maintaining blood vessel integrity and the blood-brain barrier. Hypertension increases ICH risk by damaging blood vessel integrity due to inflammatory cascades. Lower VE-cadherin levels in hypertensive patients suggest its potential as an early predictor of ICH risk. Methods: This 12-month study included 40 hypertensive control patients and 40 hypertensive patients with nonlobar ICH. Blood samples were analyzed using enzyme-linked immunosorbent assays to measure VEcadherin, interferon gamma, and interleukin-17 levels. Receiver operating characteristic analysis determined a VE-cadherin cutoff value, and a regression model assessed its association with ICH risk. Results: A VE-cadherin cutoff value of 400.8 pg/dL was identified, with higher levels independently linked to lower odds of nonlobar ICH. VE-cadherin was the only biomarker that remained statistically significant in the regression model. These findings suggest that reduced VE-cadherin levels contribute to ICH development, and its measurement may help identify high-risk patients for early intervention. Conclusion: VE-cadherin dysfunction in hypertension may serve as a predictor of nonlobar ICH risk. Its protective role highlights its potential as a biomarker for risk assessment and prevention strategies in hypertensive patients. These findings may pave the way for targeted interventions in hypertensive populations, warranting further research to confirm its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.